From pg 20:
The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies, particularly in certain diseases where it is possible to cure a large proportion of the prevalent patient pool (or at least prevent an additional dose from being required for an extended period). While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow. GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients.
$2.8million for the single dose needed to treat a child for SMA.
Pharma’s lack of conscience continues to astound.
“In some cases, doctors gave patients do-not-resuscitate orders without family or patient consent, sometimes overruling families that wanted everything done for their loved one, three nurses said.“
This is so incredibly relatable.
“Ghost networks” are insurers’ in-network provider directories that are full of outdated or incorrect information, and providers who no longer accept the insurance in question. A study of BCBS mental healthcare providers found that 75% of the listed providers were unreachable or unavailable. For pediatric psychiatrists, that number was 83%.